Adjuvant Everolimus in Patients with Completely Resected, High-risk Renal Cell Carcinoma – European Urology

European Urology shared on X:

“Platinum Priority – Kidney Cancer: Adjuvant Everolimus in Patients with Completely Resected, Very High-risk Renal Cell Carcinoma of Clear Cell Histology: Results from the Phase 3 Placebo-controlled SWOG S0931 (EVEREST) Trial by Primo Lara et al.

Read the full article here.

Come back tomorrow for the Editorial!

Adjuvant Everolimus in Patients with Completely Resected, Very High-risk Renal Cell Carcinoma of Clear Cell Histology: Results from the Phase 3 Placebo-controlled SWOG S0931 (EVEREST) Trial

Authors: Primo N. Lara, Catherine Tangen, Elisabeth I. Heath, Shuchi Gulati, Mark N. Stein, Maxwell Meng, Ajjai Shivaram Alva, Sumanta K. Pal, Igor Puzanov,  Joseph I. Clark, Toni K. Choueiri, Neeraj Agarwal, Robert Uzzo, Naomi B. Haas, Timothy W. Synold, Melissa Plets, Ulka N. Vaishampayan, Brian M. Shuch, Seth Lerner, Ian M. Thompson, Christopher W. Ryan

Source: European Oncology/X